Autoregulation of H+/lactate efflux prevents monocarboxylate transport (MCT) inhibitors from reducing glycolytic lactic acid production

Abstract

Background Pharmacological inhibition of membrane transporters is expected to reduce the flow of solutes, unless flux is restored (i.e., autoregulated) through a compensatory increase in the transmembrane driving force. Drugs acting on monocarboxylate transporters (MCTs) have been developed to disrupt glycolytic metabolism, but autoregulation would render such interventions ineffective. We evaluated whether small-molecule MCT inhibitors reduce cellular H+/lactate production. Methods Cellular assays measured the relationship between MCT activity (expressed as membrane H+/lactate permeability; PHLac) and lactic acid production (inferred from H+ and lactate excretion; JHLac) in a panel of pancreatic ductal adenocarcinoma (PDAC) cells spanning a range of glycolytic phenotype. Results MCT activity did not correlate with lactic acid production, indicating that it is not set by membrane permeability properties. MCT inhibitors did not proportionately reduce JHLac because of a compensatory increase in the transmembrane [lactate] driving force. JHLac was largely insensitive to [lactate], therefore its cytoplasmic build-up upon MCT inhibition does not hinder glycolytic production. Extracellular acidity, an MCT inhibitor, reduced JHLac but this was via cytoplasmic acidification blocking glycolytic enzymes. Conclusions We provide mathematically verified evidence that pharmacological and physiological modulators of MCTs cannot proportionately reduce lactic acid production because of the stabilising effect of autoregulation on overall flux.

Histone lactylation bridges metabolic reprogramming and epigenetic rewiring in driving carcinogenesis: Oncometabolite fuels oncogenic transcription

“…Lactic acid, a substance produced during metabolism by both the host and intestinal microbiota, has been recognised as a crucial signalling molecule in the immune system 69,101 . Notably, Sun et al.…”

“…Importantly, the transportation and detection of lactate rely on the utilisation of monocarboxylate transporter (MCT) and sodium MCT families, along with G protein‐coupled receptors (GPRs) called GPR81 and GPR132 69 . In cancer cells, glutamine serves as a vital carbon skeleton for the production of lactate and acts as an additional pathway for generating lactate.…”

Combining metformin with lactate transport inhibitors as a treatment modality for cancer - recommendation proposal

“…Thus, simultaneously blocking lactate export and complex 1 activity causes an acute drop in NAD+ levels resulting in synthetic lethality. The importance of synthetic lethality is underscored by the observation that, due to autoregulation of lactate efflux, merely blocking lactate transporters alone is not sufficient to reduce glycolytic flux to lactate (14). This synthetic lethality has been independently reported in multiple studies.…”

Heterocyclic and non‐heterocyclic arena of monocarboxylate transporter inhibitors to battle tumorigenesis

“…So, the investigators focused on MCT to develop novel anti‐cancer agents. They have been trying to create small molecules as MCT inhibitors, which can inhibit abnormal lactate production (Blaszczak et al, 2022). The development of MCT inhibitors has paved the possibilities for cancer treatment.…”